Berry Extract for Presbyopia: What a Small Trial Really Found

A berry supplement will not replace your reading glasses on the strength of the evidence now available. A 2026 randomized crossover trial found modest improvements in selected near-vision measures after six weeks of a standardized berry extract, but it enrolled only 23 adults, reported no effect sizes or confidence intervals in the published abstract, and did not establish that the extract changes the structural causes of presbyopia.

The formulation, called AKB, combines extracts of Aronia melanocarpa, Lonicera caerulea, and Vaccinium myrtillus. It contains at least 25% anthocyanins and 4.5% iridoids. Those compounds have plausible biological effects in other settings. Plausibility, however, is not proof that a capsule restores the flexibility of an aging lens.

What the 2026 trial found

In the 2026 AKB trial, 23 adults older than 50 received either 400 mg of AKB twice daily or placebo for six weeks, then crossed over to the other treatment after a five-week washout. The randomized, double-blind, placebo-controlled crossover design is a sensible choice for a small study: each participant can serve as their own comparison.

Compared with placebo, AKB was associated with improvements in near contrast sensitivity and visual-field parameters. The authors described those improvements as modest and exploratory. They described changes in visual evoked potential latency and optical coherence tomography measurements as "directionally favourable," but the abstract does not provide numerical results, p-values, confidence intervals, or effect sizes for any visual endpoint.

That omission blocks the question readers actually need answered: how large was the change, how variable was it, and would it make reading easier in daily life? A statistically detectable shift on a psychophysical test can still be too small to matter outside the clinic. Without the quantitative results, clinical importance cannot be judged.

"Selected" outcomes deserve scrutiny

The wording of the title matters. The trial says the extract improved "selected visual function outcomes," not visual function as a whole. That does not by itself prove cherry-picking, but it signals that the researchers assessed more than the outcomes emphasized in the headline.

The publicly available abstract does not cite a trial registration number. Prospective registration lets readers compare reported outcomes with the outcomes researchers specified before seeing the results. Without it, readers cannot audit the primary endpoint, the number of tests performed, or whether favorable results received more attention than null results. In a 23-person study with several visual and biomarker measures, that uncertainty carries real weight.

Near contrast sensitivity and visual-field testing also depend on participant responses. Double blinding and a placebo reduce expectation effects, but they do not erase normal test-retest variation or learning effects. The publication does not report a formal assessment of whether participants guessed which treatment they received.

A crossover trial can efficiently detect a large, short-term signal. It cannot turn exploratory secondary outcomes into proof that a supplement reverses presbyopia.

The biomarker story is weaker than it sounds

The researchers measured circulating αA-crystallin, αB-crystallin, ALDH1A1, and TRPV4, describing changes in these markers as exploratory. None has a validated reference range or established role as a human surrogate for accommodation, ciliary-muscle function, or presbyopia progression. A blood-level change in a broadly expressed protein is not evidence that the lens has become more elastic.

The more relevant mechanistic findings were null. AKB did not change advanced glycation end-products or systemic antioxidant enzymes. That matters because lens protein crosslinking, oxidative stress, and loss of lens elasticity are central to the biological rationale for using these compounds. A null blood biomarker result does not disprove every possible mechanism, but it removes an expected piece of support for the proposed anti-glycation or antioxidant explanation.

Six weeks also seems short for reversing structural changes that accumulate over decades. If AKB affected visual performance, the current study does not show whether the effect was durable, whether it reflected a transient functional change, or whether it altered the course of presbyopia.

One research program is not independent confirmation

The only earlier human study of this specific extract appears to come from the same research group. Their 2024 study reported improved near visual acuity in people with presbyopia. That consistency can justify a better trial, but it does not provide independent replication. Two papers from one group using the same proprietary preparation answer a narrower question: can that group reproduce its own finding?

Other anthocyanin trials do not fill that gap. A 2023 randomized, double-blind, placebo-controlled trial in late-adulthood volunteers found improvements in cognitive measures and eye-dryness scores with an anthocyanin-rich ingredient. Eye dryness concerns the tear film and ocular surface. Presbyopia concerns accommodation and lens elasticity. The two conditions share an address, not a mechanism.

Anthocyanins do have measurable activity in non-vision research. In a 2025 crossover trial, healthy middle-aged adults consumed a blackcurrant beverage or placebo with high-fat meals; researchers measured acute cardiovascular-risk markers, not vision. A 2023 observational study also linked dietary anthocyanin sources with metabolomic patterns and cardiometabolic risk factors. The first study supports short-term vascular bioactivity; the second reports associations, not causation. Neither shows improved accommodation.

Pharmacokinetic data add one modest point in the AKB trial's favor. A 2023 tart-cherry study found that parent anthocyanins clear from plasma over hours, so a five-week washout should be ample for those compounds. The AKB formulation also contains iridoids, whose human metabolic kinetics remain poorly characterized, so carryover from that component cannot be ruled out as confidently.

What stronger evidence would look like

Age-related outcomes often need larger and longer studies. A 2024 multi-study randomized investigation of wild blueberry extract in healthy older adults found that low-anthocyanin powder doses did not produce significant effects, with meaningful outcomes appearing only at higher extract concentrations. It measured cognitive and cardiovascular outcomes, not vision, but it illustrates how dose and precision can determine whether an apparent signal holds up.

Likewise, a 24-week randomized trial of oral anthocyanins in older adults at risk for dementia evaluated cognition and blood-based dementia biomarkers. It does not answer the presbyopia question. It does show the scale of work needed before claims about aging biology become actionable.

A convincing AKB study would prospectively register a primary near-vision endpoint, report every measured visual outcome with effect sizes and confidence intervals, test whether any change improves daily reading performance, and be replicated by an independent group. It would also need a longer follow-up if the claim is slowed progression or structural improvement rather than a short-lived performance effect.

The practical verdict

AKB is an interesting hypothesis, not a reading-glasses replacement. The 2026 trial has a legitimate design strength—within-person comparison under blinding—but its small sample, selected-outcome framing, unregistered endpoint hierarchy in the available record, and absent quantitative reporting sharply limit confidence.

Anthocyanin-rich foods and extracts may be worth considering for other reasons, particularly cardiovascular or metabolic questions with a separate evidence base. Do not use that broader biology as evidence that a berry pill restores near vision. For presbyopia, corrective lenses and established clinical options remain the interventions with evidence that patients can actually use.